OICR Invests $49M in Genomics, Translational Research Programs | GenomeWeb

NEW YORK (GenomeWeb News) – The Ontario Institute for Cancer Research has pumped C$52 million ($49.3 million) into several genomic and translational research programs aimed at developing new diagnostics and treatments for cancer, OICR said today.

The new investment will concentrate on supporting programs and research areas that the institute deems to be of high interest, including ones centering on cancer genomics and stem cells, drug discovery, informatics, and pathology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.